急性リンパ性白血病（ALL）は、未熟なリンパ球が多数生成されることによって通常の血球の産生が妨げられている白血球の癌で、血液や、脾臓やリンパ節および肝臓などの体の他の部分にも急速に入ってきます。危険因子として、放射線や化学薬品への曝露、年齢、ウイルス感染、遺伝要因などが挙げられます。徴候は、貧血、頻繁な感染症、あざができやすくなる、骨の痛み、呼吸疾患などがあります。治療には、化学療法、輸血、移植、薬物療法が用いられます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, 2022
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
